Qi Cai

Dr. Qi Cai

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in Seminars in Diagnostic Pathology
Verified
Journal Article
Closed access
QCQi Cai
Qi Cai
AHAllen R. Hendricks
Allen R. Hendricks

1 January 2001 in World Journal of Gastroenterology
Verified
Journal Article
Open access
QCQi Cai
Qi Cai
MSMeng-Hong Sun
Meng-Hong Sun
HLHong-Fen Lu
Hong-Fen Lu
TZTai-Ming Zhang
Tai-Ming Zhang
SMShan-Jing Mo
Shan-Jing Mo
DSDa-Ren Shi
Da-Ren Shi
Clinicopathological and molecular genetic analysis of 4 typical Chinese HNPCC families

11 March 2025 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Closed access
PKPayal Kapur
Payal Kapur
HZHua Zhong
Hua Zhong
ACAlana Christie
Alana Christie
HXHaitao Xu
Haitao Xu
QCQi Cai
Qi Cai
JBJames Brugarolas
James Brugarolas
Background: The mechanisms underlying metastatic latency in renal cell carcinoma (RCC) remain poorly understood. Methods: This study evaluated 2 large independent cohorts for differences in tumor biology between patients who developed metastases early (≤1 year after nephrectomy) and those with late onset (>3 years). Results: In the discovery cohort (n = 161), late metastatic RCC was associated with clear cell histology (88.9% vs 78.7%), lower pathological stage (pT1-2; 40.3% vs 18.0%), and favorable histopathological features including low grade (40.0% vs 2.3%), less sarcomatoid (5.6% vs 21.8%), and reduced necrosis (37.7% vs 78.3%; all P < .02). Late metastatic RCC tumors exhibited increased angiogenesis (63.5% vs 19.4%) and reduced inflammation (78.8% vs 50.0%; all P < .02) profiles. Genomic driver analyses revealed comparable rates of PBRM1 and SETD2 loss in late and early metastatic RCC, while BAP1 loss was significantly less common in late metastatic RCC (7.5% vs 27.1%; P < .02). In multivariable models, BAP1/PBRM1/SETD2 status and tumor necrosis emerged as key discriminators of late metastatic RCCs. These findings were confirmed in the second cohort (n = 307). Late metastatic RCC was enriched for fatty acid oxidation and angiogenesis pathways, supporting a less aggressive phenotype. This was further evidenced by a lower engraftment rate in murine models (0% vs 36.5%; P < .001) and significantly longer overall survival from the time of metastasis (median survival doubled, P < .001). Interestingly, late metastatic RCC shared genomic and phenotypic features with RCC that metastasizes to the pancreas, suggesting a common underlying biology influencing both metastatic latency and pancreatic tropism. Conclusions: Overall, these findings advocate for recognition of late metastatic RCC because of its distinct biology and improved prognosis.

6 November 2023 in Advances in Anatomic Pathology
Verified
Journal Article
Closed access
QCQi Cai
Qi Cai
JGJeffrey Gagan
Jeffrey Gagan
PKPrasad Koduru
Prasad Koduru
JCJeffrey Cadeddu
Jeffrey Cadeddu
RSRajal B. Shah
Rajal B. Shah
DPDoreen N. Palsgrove
Doreen N. Palsgrove
TFE3-rearranged renal cell carcinoma (RCC) is a distinct, uncommon entity with more than 20 different fusion partners identified; however, histomorphology may be suggestive of specific fusion partners in select TFE3-rearranged RCCs. For example, most MED15::TFE3 fusion associated RCCs exhibit multilocular cystic morphology, mimicking multilocular cystic renal neoplasm of low malignant potential. Here we present a case of MED15::TFE3 RCC in an older adult and review the literature with an emphasis on practical diagnostic approaches for predominantly cystic, low-grade, clear cell renal tumors.

1 September 2020 in Transplantation
Verified
Journal Article
Open access
SMSamantha Moore
Samantha Moore
CMChristopher Metter
Christopher Metter
QCQi Cai
Qi Cai
Jose TorrealbaJose Torrealba
Jose Torrealba

10 May 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
MLMatthew Lee
Matthew Lee
QCQi Cai
Qi Cai
JWJue Wang
Jue Wang
Immune checkpoint inhibitors (ICIs) have transformed oncologic care and are increasingly used as adjuvant therapy to reduce the risk of recurrence. However, this shift has introduced immune-related adverse events (irAEs) to patients who may otherwise be clinically disease-free after definitive therapy. Sarcoidosis-like reaction (SLR) is an uncommon but important irAE characterized by non-necrotizing granulomatous inflammation. In the adjuvant setting, SLR is uniquely consequential because it can closely mimic recurrent malignancy on surveillance imaging and thereby prompt unnecessary diagnostic procedures, treatment interruption, or escalation of care. This review summarizes the current evidence on ICI-associated SLR with an emphasis on adjuvant immunotherapy, where practical guidance remains limited. We integrate evidence from clinical trials, real-world cohorts, and published case series to summarize the reported incidence of SLR, proposed immunologic mechanisms, clinical and radiographic presentation, pathology, differential diagnosis, and management. Particular attention is given to the problem of distinguishing SLR from recurrence, when tissue confirmation should be prioritized, and how management should be individualized according to clinical severity and organ involvement. Common radiographic features include bilateral mediastinal and hilar lymphadenopathy and pulmonary nodules, but tissue confirmation remains the diagnostic gold standard when feasible. Many cases are low grade and may be managed conservatively. Greater recognition of ICI-associated SLR is critical to avoid misdiagnosis and unnecessary escalation of care while preserving the therapeutic benefit of adjuvant immunotherapy.